The double-blind, double-dummy trial randomized 818 adults with CKD and type 2 diabetes [urine albumin–creatinine ratio (UACR) ≥100 to <5000 mg/g] to receive once-daily finerenone plus empagliflozin, finerenone alone or empagliflozin alone, all in addition to a renin–angiotensin system inhibitor. The gene discussed is REN; the disease is chronic kidney disease.